$6.17▴ 42.17%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-321.92MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+22.0%year over year
Decelerating
Still growing fast, but the pace has been easing.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Iovance Biotherapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Still growing fast, but the pace has been easing.
Key numbers
Profitability
Net margin-160.4%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$248.16M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.